Chemo delivered straight to the brain: new hope for deadly tumors?

NCT ID NCT01386710

Terminated Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a technique that delivers two cancer drugs, bevacizumab and carboplatin, directly into the brain's arteries for people with recurrent glioblastoma or anaplastic astrocytoma. The goal is to see if this method is safe and can slow tumor growth better than standard IV delivery. The trial is currently suspended and includes 54 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab and carboplatin
What this could lead to: If it works, this could offer a new way to deliver chemotherapy directly to the brain for recurrent glioblastoma, potentially improving survival.
What could go wrong: This trial is early (Phase I/II) and currently suspended. The approach is complex and carries risks from intraarterial infusion and chemotherapy side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma anaplastic oligoastrocytoma astrocytoma (excluding glioblastoma) glioblastoma glioma susceptibility 1 neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC ASTROCYTOMA GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Lenox Hill Brain Tumor Center

New York, New York, 10075, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.